223 related articles for article (PubMed ID: 32882611)
1. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of selective RET inhibitors via scaffold hopping.
Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
[TBL] [Abstract][Full Text] [Related]
4. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
5. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
[TBL] [Abstract][Full Text] [Related]
6. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
[TBL] [Abstract][Full Text] [Related]
7. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
8. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract][Full Text] [Related]
10. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
11. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
12. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
Lakkaniga NR; Gunaganti N; Zhang L; Belachew B; Frett B; Leung YK; Li HY
Eur J Med Chem; 2020 Nov; 206():112691. PubMed ID: 32823007
[TBL] [Abstract][Full Text] [Related]
15. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
16. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
Saha D; Ryan KR; Lakkaniga NR; Smith EL; Frett B
ChemMedChem; 2021 May; 16(10):1605-1608. PubMed ID: 33559353
[TBL] [Abstract][Full Text] [Related]
17. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K; He R; Li Z; Qiu K; Xiao G; Peng L; Meng X; Zheng C; Zhang Z; Cai Q
Eur J Med Chem; 2023 May; 251():115237. PubMed ID: 36905915
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
